loader image
Thursday, December 18, 2025
75.4 F
McAllen
- Advertisement -

AMA Webinar Provides Update on COVID-19 Therapeutics and Other Treatment Options

Translate to Spanish or other 102 languages!

Fact-based insights on COVID-19 therapeutic drugs and other treatment options from the nation’s highest-ranking subject matter experts. Image for illustration purposes.
Paxlovid and Molnupiravir—two therapeutics used in treating COVID-19. Image for illustration purposes.

Mega Doctor News

- Advertisement -

The AMA’s COVID-19 webinar series continues this week by bringing the physician community the latest fact-based insights on COVID-19 therapeutic drugs and other treatment options from the nation’s highest-ranking subject matter experts.

During the tenth episode in the webinar series, AMA Immediate Past President Susan R. Bailey, M.D. will host several infectious disease experts from the Food and Drug Administration (FDA) to provide physicians with the most up-to-date information on Paxlovid and Molnupiravir—two therapeutics used in treating COVID-19. They will also discuss alternative treatment options for high-risk outpatients with mild-moderate COVID-19. 

 
What: AMA webinar series, episode 10: therapeutics and other treatment options

When:  Tuesday, February 1, 2022, 1 p.m. Central | 2 p.m. Eastern

Who:   Susan R. Bailey, M.D., AMA Immediate Past President

- Advertisement -

Stephanie Troy, M.D., FDA Senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs

Aimee Hodowanec, M.D., FDA Senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs

John Farley, M.D., M.P.H., FDA Director of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs

Registration: To watch the live webinar, register here

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health and Brownsville Join Forces on Major Hospital Expansion

The City of Brownsville and DHR Health announced a new public-private partnership to expand DHR Health Brownsville, marking a major investment in local healthcare and economic development

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.

Early Findings Show Breast Cancer Vaccine Produces Immune Response

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine. 

DHR Health Awarded Large Employer of the Year by Texas Workforce Commission

Workforce Solutions Lower Rio Grande Valley (WFS) proudly announced that its nominee, DHR Health, has been awarded the Large Employer of the Year Award at the 28th Annual Texas Workforce Commission (TWC) Conference.
- Advertisement -
×